Letairis (Ambrisentan) Patent Expiration, LOE Window & CMS Spending

Letairis (Ambrisentan) by Gilead Sciences: FDA Orange Book LOE 2031-10-14, 7 AB generics, $120.2M 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN022081 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-10-14
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors7
2024 CMS Total Public Spend$120.2M
2024 Medicare Part D Spend$82.7M
2024 Medicaid Spend$37.5M
Reported Wholesale Price Change (CA SB 17)16 WAC filings (max 22.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.